CN101245051B - 2,4-di-substituted amido-6-substituted-[1,3,5]triazine or miazines compound, preparation method, pharmaceutical combination and use of the same - Google Patents
2,4-di-substituted amido-6-substituted-[1,3,5]triazine or miazines compound, preparation method, pharmaceutical combination and use of the same Download PDFInfo
- Publication number
- CN101245051B CN101245051B CN2006101700247A CN200610170024A CN101245051B CN 101245051 B CN101245051 B CN 101245051B CN 2006101700247 A CN2006101700247 A CN 2006101700247A CN 200610170024 A CN200610170024 A CN 200610170024A CN 101245051 B CN101245051 B CN 101245051B
- Authority
- CN
- China
- Prior art keywords
- triazine
- acid
- anilino
- base
- morpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 title description 18
- -1 2,4-disubstituted amino-6-substituted-[1,3,5]triazine Chemical class 0.000 claims abstract description 123
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract 5
- 230000036436 anti-hiv Effects 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- XRKIHUXCUIFHAS-UHFFFAOYSA-N [4-(3-methoxy-3-oxopropyl)phenyl]boronic acid Chemical compound COC(=O)CCC1=CC=C(B(O)O)C=C1 XRKIHUXCUIFHAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 11
- 230000027455 binding Effects 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 8
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 abstract description 4
- 102100034343 Integrase Human genes 0.000 abstract description 3
- 108010061833 Integrases Proteins 0.000 abstract description 3
- 229940124524 integrase inhibitor Drugs 0.000 abstract description 3
- 239000002850 integrase inhibitor Substances 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 66
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 45
- 239000002585 base Substances 0.000 description 44
- 239000002994 raw material Substances 0.000 description 41
- 239000003153 chemical reaction reagent Substances 0.000 description 37
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 28
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- VOIZNVUXCQLQHS-UHFFFAOYSA-N 3-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1 VOIZNVUXCQLQHS-UHFFFAOYSA-N 0.000 description 15
- 208000030507 AIDS Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 150000003918 triazines Chemical class 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 239000003513 alkali Substances 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- HTSVYUUXJSMGQC-UHFFFAOYSA-N 2-chloro-1,3,5-triazine Chemical compound ClC1=NC=NC=N1 HTSVYUUXJSMGQC-UHFFFAOYSA-N 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000000967 suction filtration Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- QSACCXVHEVWNMX-UHFFFAOYSA-N N-acetylanthranilic acid Chemical compound CC(=O)NC1=CC=CC=C1C(O)=O QSACCXVHEVWNMX-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- PBOOZQFGWNZNQE-UHFFFAOYSA-N 3-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Br)=C1 PBOOZQFGWNZNQE-UHFFFAOYSA-N 0.000 description 6
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- RJCAAMLCPGTVJH-UHFFFAOYSA-N C(C(C)(C)C)(=O)C1=CC(=C(C(=O)O)C=C1)N Chemical compound C(C(C)(C)C)(=O)C1=CC(=C(C(=O)O)C=C1)N RJCAAMLCPGTVJH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LBZHEJNCDDSGCU-UHFFFAOYSA-N tert-butyl 1-amino-4-anilino-6-chloro-2H-1,3,5-triazine-2-carboxylate Chemical class C(=O)(OC(C)(C)C)C1N(C(=NC(=N1)NC1=CC=CC=C1)Cl)N LBZHEJNCDDSGCU-UHFFFAOYSA-N 0.000 description 4
- KSGWLNWYCHAFIX-UHFFFAOYSA-N triazine-4,5-diamine Chemical class NC1=CN=NN=C1N KSGWLNWYCHAFIX-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 3
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 3
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 3
- HAQSNNCKMWHVNM-UHFFFAOYSA-N 2-phenyl-1H-pyrimidine-2,4-diamine Chemical class N1C=CC(N)=NC1(N)C1=CC=CC=C1 HAQSNNCKMWHVNM-UHFFFAOYSA-N 0.000 description 3
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 3
- 0 C*(C1CC1)N(C)c1nc(NN)nc(N(*)*)n1 Chemical compound C*(C1CC1)N(C)c1nc(NN)nc(N(*)*)n1 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000003956 methylamines Chemical class 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 2
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 2
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000005554 pickling Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical group OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- UDKGXKYEWBGQCG-UHFFFAOYSA-N 1-bromo-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Br)=C1 UDKGXKYEWBGQCG-UHFFFAOYSA-N 0.000 description 1
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical class CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- FBFNMTGUOBUGFQ-UHFFFAOYSA-M 2-(2,5-diphenyltetrazol-1-ium-1-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=C(C=2C=CC=CC=2)N=NN1C1=CC=CC=C1 FBFNMTGUOBUGFQ-UHFFFAOYSA-M 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- ODJFDWIECLJWSR-UHFFFAOYSA-N 3-bromobenzamide Chemical compound NC(=O)C1=CC=CC(Br)=C1 ODJFDWIECLJWSR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
- WBIZZNFQJPOKDK-UHFFFAOYSA-N 4-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=CC(O)=CC=C1C=O WBIZZNFQJPOKDK-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OIFWQOKDSPDILA-XLPZGREQSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 OIFWQOKDSPDILA-XLPZGREQSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 229960004643 cupric oxide Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- DWLVWMUCHSLGSU-UHFFFAOYSA-N dimethylcarbamic acid Chemical compound CN(C)C(O)=O DWLVWMUCHSLGSU-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- JVQPSLMSWPIJKT-UHFFFAOYSA-N quinoline styrene Chemical compound C=Cc1ccccc1.c1ccc2ncccc2c1 JVQPSLMSWPIJKT-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 108010042747 stallimycin Proteins 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种新型的2，4-二取代氨基-6-取代-[1，3，5]三嗪或1，3-嘧啶衍生物及其制备方法、药物组合物和其药理用途，其结构通式如式(I)所示，其中R1、R2、R3、R4、R5、R6、A、B、X、Y和Z的定义如说明书中所述。该类化合物与HIV-1整合酶具有很高结合活性，并且在底物竞争测试中能够有效的抑制整合酶对底物的结合。因此该类化合物是较强的HIV-1整合酶抑制剂，有望开发成为新的抗HIV病毒药物。 A novel 2,4-disubstituted amino-6-substituted-[1,3,5]triazine or 1,3-pyrimidine derivative and its preparation method, pharmaceutical composition and pharmacological use, its general structural formula As shown in formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, B, X, Y and Z are as defined in the specification. The compounds have high binding activity to HIV-1 integrase, and can effectively inhibit the binding of integrase to substrates in the substrate competition test. Therefore, this type of compound is a strong HIV-1 integrase inhibitor, and is expected to be developed into a new anti-HIV drug. 
Description
Technical field
The present invention relates to pharmaceutical chemistry and pharmacotherapeutics field, be specifically related to 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1,3-pyrimidines, its preparation method, the pharmaceutical composition that contains this compounds and purposes.
Background technology
From 1981 since the U.S. finds the first acquired immune deficiency syndrome (AIDS) AIDS (acquiredimmunodeficiency syndrome, acquired immunodeficiency disease disease) patient, acquired immune deficiency syndrome (AIDS) spreads fast in more than 180 countries and regions in the whole world.Present global AIDS patient and virus carrier's sum have reached more than 4,200 ten thousand, and this is state-owned nearly 1,000,000 in wherein, occupies the 2nd in the Asia, occupies the 14th in the whole world.And the China's AIDS case load has become an increasingly serious public safety problem increasing fast with 30～40% speed every year on average in recent years.
HIV virus is as the pathogenic agent of AIDS, and it infects behind human body in vivo reproduction process needs intergrase (integrase, participation IN) just can be finished.IN can finish the process that the HIV double chain DNA molecule is integrated into host chromosome.IN has the endonuclease activity and the chain transfer activity of 3 ' cutting in vivo.IN cuts two bases at the double-stranded two ends of the linear flush end DNA of HIV by 3 '-5 ' direction earlier, forms the recessed end of CA-OH-3 ', cuts the breach of a 5bp on the dna double chain of host cell; The recessed end of the CA-OH-3 ' of HIV dna double chain combines with the form of phosphodiester bond with the 5bp of host cell DNA chain otch under the effect of IN then, forms to integrate intermediate; In cell, remove viral DNA 5 ' terminal unpaired two bases again under the mechanism of action of some enzyme, repair the breach of virus and host cell DNA chain.
The protein of the molecular weight 32kD that IN is made up of 288 amino acid, it structurally is divided into three parts: N petiolarea, core area and C petiolarea.The N petiolarea is made up of 1～50 amino acids, is a conservative HHCC Zinc finger domain, has the viral DNA recognition function, promotes the function of IN four dimerizations and enhancing catalytic activity in addition in addition.Core area is made up of 52～210 amino acids, is the most important position of IN catalysis.It comprises three acidic amino acid residues (Asp64, Asp116 and Glu152), is arranged in the DD35E type, is very conservative structure, is the site of interior ribozyme and nucleotidyltransferase.This position and one or two divalent cation (Mg
2+Or Mn
2+) in conjunction with being essential to catalytic activity.The C petiolarea is the zone of conservative property minimum among the IN, is made up of 213～288 amino acids.It comprises nuclear localization signal, can be nonspecific in conjunction with DNA, also participate in the multimerization of IN.The crystalline structure in three districts of IN reaches and the compound crystal structure of various inhibitor all obtains, but the crystalline structure of IN total length does not still solve.
Because IN plays indispensable vital role in the HIV virus replication, and IN do not have the functional analogue of IN in human body cell, thereby IN is the desirable target of AIDS treatment.Seeking new IN inhibitor, in conjunction with hiv reverse transcriptase and proteinase inhibitor drug combination, can improve antiviral activity, reduce toxic side effect and reduce resistance, is treatment plan highly significant.
Up to the present the inhibitor of the IN of Fa Xianing comprises: DNA wedding agent, oligonucleotide and nucleoside analog, sulfuric ester analogue, polypeptide and hydroxyl substituted aromatics etc.Follow the binding site of IN can be divided into four classes according to these inhibitor.
1 nucleosides binding site
The nucleoside compound that is used as the research of IN inhibitor the earliest is AZT and derivative AZTMP thereof.The single phosphoric acid of AZT, bis phosphoric acid and triphosphoric acid all have anti-IN chain transfer activity.They are by disturbing IN to realize with combining of DNA to the inhibition of IN.The K156 of IN, K159 and K160 are the binding sites of monokaryon glycosides, and wherein the K159 of high conservative is IN and DNA bonded key.Find dinucleotide and different dinucleotide subsequently, also have the oligonucleotide compounds that the activity that suppresses IN is also arranged.
2 metal ion binding sites
Divalent-metal ion (the Mg of polyhydroxy fragrant compound and IN
2+Or Mn
2+) thereby chelating suppresses the activity of IN.This has and is in the news at most in the inhibiting compound of IN, lignanolide class, coumarin monomeric or dimer class, vinylbenzene quinoline is arranged and contain volution class anthraquinone class of pyrocatechol etc.This compounds has the good restraining effect to IN in external test, but too big in the cell cultures toxic.
3LTR (long terminal repetition) dna sequence dna binding site
This class inhibitor has been reported at present dna double spiral minor groove binding (as spindle mycin and distamycin), DNA intercalator (as Dx) and topoisomerase enzyme inhibitor (as the many anthraquinones of rice).
4 other sites
Merck ﹠ Co., Inc. had found the two kinds of diketone acid inhibitor that can contain IN in 2000, and this is that a unique so far class selectively acting is in the inhibitor of IN.This compounds is to the selective restraining effect of second step of integrating remark.In addition other inhibitor all may have a plurality of action sites simultaneously.
Although to the research in surplus the inhibitor of IN existing ten year, the IN inhibitor did not have the medicine listing at present, there only have minority to enter to be clinical.Trace it to its cause, mainly contain the restriction of two aspects: the one, the restriction of activity determination method: can't determine based on the mensuration of cell cultures whether compound directly acts on IN, and the screening of molecular level has too many false positive; The 2nd, the crystalline structure of the crystalline structure of the restriction of structure biology aspect: IN and DNA substrate complex thereof all do not have to determine, and integrates in this complicated biological process and also have many mechanism not understand.
At present the treatment of AIDS disease is mainly adopted the strategy of drug combination, promptly adopt hiv reverse transcriptase and proteinase inhibitor drug combination, but the toxic side effect situation of resistance that the HIV virus mutation causes in the therapeutic process and reversed transcriptive enzyme and proteinase inhibitor is serious.Therefore, seek and find that the HIV-1 integrase inhibitor becomes the new important theme of AIDS treatment.From natural product, find the new inhibitor of HIV-1 intergrase, have great ground-breaking meaning for the treatment of effective HIV-1 integrase inhibitor of further design synthesizing new and AIDS.
Summary of the invention
An object of the present invention is to provide and had the novel 2 of anti HIV-1 virus effect, 4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, the 3-pyrimidines, its general structure is suc as formula shown in (I).
Another object of the present invention provides with 2,4,6-three chloro-[1,3,5] triazine or 1, and the 3-pyrimidine is 2 of a raw material synthesizing new, 4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, the method for 3-pyrimidines.
A further object of the present invention provides and comprises 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, the pharmaceutical composition of the application of the anti HIV-1 virus aspect of 3-pyrimidines.
Compound involved in the present invention can be used as the micromolecular inhibitor of HIV-1 intergrase, and the HIV double chain DNA molecule that participates in by blocking-up IN is integrated into the process of host chromosome, thereby plays the effect that suppresses virus replication.Therefore, be expected to develop and become new anti HIV-1 virus medicine.
The invention provides and have 2 of following general formula (I) structure, 4-disubstituted amido-6-replacement-[1,3,5] triazine or 1,3-pyrimidines or its pharmacy acceptable salt:
Wherein:
X is selected from C or N.
Y is selected from O or NH.
A is selected from CH, CH
2, N or NH.
B is selected from CH, CH
2, N or NH.
Z represents the group of atom or atom.Wherein, described atom is carbon atom or nitrogen-atoms, and the group of described atom is alkoxyl group, sulfydryl, the acyl group of C1～C4 and the carbon atom that group replaced of aromatic base Ar of the straight or branched alkyl of the alkyl, the C1～C6 that are selected from hydrogen atom, halogen, halo C1～C3, cyano group, nitro, amino, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, carboxyl, C1～C4.
N is selected from 0 to 3 integer.
Dotted line is represented singly-bound or two key.
R
1Be selected from hydrogen, C
1～C
6Saturated or the unsaturated alkyl of straight or branched, C
3～C
7Cyclic hydrocarbon radical, alkyloyl RCO, aromaticacyl radical ArCO, alkane alkylsulfonyl RSO
2, fragrant alkylsulfonyl ArSO
2, benzyl, aromatic base Ar, 5～7 membered aromatic heterocycles (contain 1～3 heteroatoms that is selected from oxygen, sulphur, nitrogen, can and close by phenyl and aromatic heterocycle, or by one or more halogen, C of being selected from
1～C
6Straight or branched alkyl, cyano group, nitro, amino, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, carboxyl, C
1～C
4Alkoxyl group, sulfydryl, C
1～C
4The group of acyl group, aromatic base Ar replaces).
R
2Be selected from hydrogen, halogen, C
1～C
6Straight or branched alkyl, C
1～C
4Straight or branched alkoxyl group, cyano group, trifluoromethyl, trifluoromethoxy, R
1The Y-group.
R
3, R
4, R
5And R
6Be selected from hydrogen, C independently of one another
1～C
6Saturated or the unsaturated alkyl of straight or branched and alkoxyl group, C
3～C
7Cyclic hydrocarbon radical, benzyl, aromatic base Ar, 5～7 membered aromatic heterocycles (contain 1～3 heteroatoms that is selected from oxygen, sulphur, nitrogen, can and close by phenyl and aromatic heterocycle, or by one or more halogen, C of being selected from
1～C
6Straight or branched alkyl, cyano group, nitro, amino, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, carboxyl, C
1～C
4Alkoxyl group, sulfydryl, C
1～C
4The group of acyl group, aromatic base Ar replaces).
Aromatic base Ar can be a phenyl, (substituting group can be 1～4 and be selected from halogen, C substituted-phenyl
1～C
6Straight or branched alkyl, cyano group, nitro, amino, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, carboxyl, C
1～C
4Alkoxyl group, sulfydryl, C
1～C
4The group of acyl group), naphthyl, xenyl.
" pharmacy acceptable salt " described in this specification sheets can be enumerated and propionic acid particularly, oxalic acid, propanedioic acid, succsinic acid, fumaric acid, toxilic acid, lactic acid, oxysuccinic acid, tartrate, citric acid, Deng organic acid and aspartic acid, acidic amino acids such as L-glutamic acid form behind the ester salt that forms with mineral alkali again, as sodium, potassium, calcium, aluminium salt and ammonium salt, or the salt that forms with organic bases, as methylamine salt, ethylamine salt, ethanolamine salt etc., or and Methionin, arginine, basic aminoacidss such as ornithine form the hydrochloric acid behind the ester, Hydrogen bromide, hydrofluoric acid, sulfuric acid, nitric acid, the salt of mineral acids such as phosphoric acid, or and formic acid, acetate, picric acid, methylsulfonic acid, organic acid salt such as ethyl sulfonic acid.
A preferred embodiment of formula of the present invention (I) compound is following 2, and 4-disubstituted amido-6-replaces-[1,3,5] compound in triazine class or its pharmacy acceptable salt:
Wherein, X is N; Y is O;
A, B, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
Another preferred embodiment of formula of the present invention (I) compound is following 2, and 4-disubstituted amido-6-replaces-[1,3,5] compound in triazine class or its pharmacy acceptable salt:
Wherein, X is N; Y is NH;
A, B, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
Another preferred embodiment of formula of the present invention (I) compound is following 2, and 4-disubstituted amido-6-replaces-1,3-pyrimidines or its pharmacy acceptable salt:
Wherein, X is C; Y is O;
A, B, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The 4th preferred embodiment of formula of the present invention (I) compound is following 2, and 4-disubstituted amido-6-replaces-1,3-pyrimidines or its pharmacy acceptable salt:
Wherein, X is C; Y is NH;
A, B, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The 5th preferred embodiment of formula of the present invention (I) compound is following 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, and 3-pyrimidines or its pharmacy acceptable salt:
Wherein, A is C; B is N;
X, Y, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The 6th preferred embodiment of formula of the present invention (I) compound is following 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, and 3-pyrimidines or its pharmacy acceptable salt:
Wherein, A is CH; B is CH;
X, Y, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The 7th preferred embodiment of formula of the present invention (I) compound is following 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, and 3-pyrimidines or its pharmacy acceptable salt:
Wherein, A is CH; B is N;
X, Y, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The 8th preferred embodiment of formula of the present invention (I) compound is following 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, and 3-pyrimidines or its pharmacy acceptable salt:
Wherein, A is N; B is CH;
X, Y, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The 9th preferred embodiment of formula of the present invention (I) compound is following 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, and 3-pyrimidines or its pharmacy acceptable salt:
Wherein, A is N; B is N;
X, Y, Z, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
The tenth preferred embodiment of formula of the present invention (I) compound is following 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, and 3-pyrimidines or its pharmacy acceptable salt:
Wherein, Z is NH;
X, Y, A, B, n, R
1, R
2, R
3, R
4, R
5And R
6Definition as mentioned above.
Concrete preferred embodiment of the present invention is selected from following compounds:
4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-and the hydrazono-methyl]-1, the 3-dihydroxy-benzene,
2-chloroformic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
Phenylformic acid 3-benzoyloxy-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
2-acetoxy-benzoic acid 3-(2-acetoxyl group benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
4-pivaloyl aminobenzoic acid 3-(4-pivaloyl oxygen base benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
2 hydroxybenzoic acid 3-(2-(2-hydroxybenzoyl) oxygen base)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
2-benzaminic acid 3-(2-aminobenzoic acyl-oxygen base)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
2-acetylamino benzoic acid 3-(2-kharophen benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
N, N-dimethylamino formic acid 3-(N, N-formyl oxygen dimethylamino)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
N-methylamino-formic acid 3-(N-methylamino-methanoyl)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
Succinic Acid 3-(3-hydroxyl formyl radical propionyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
Phenylformic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
4-{N '-[4-(3-the bromo-benzyloxy-)-rare base of 2-methoxyl group-benzyl]-diazanyl }-6-morpholine-4-base-[1,3,5]-triazine-2-yl }-aniline,
3-bromo-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
4-trifluoromethylbenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
4-toluene sulfonic acide acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
3-bromo-benzoic acid 2-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
3-bromo-benzoic acid 2-oxyethyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
3-bromo-benzoic acid 3-methoxyl group-4-{[4-phenylamino-6-(4-sulfamyl phenylamino)-[1,3,5] triazine-2-yl]-the hydrazine methene }-phenyl ester,
4-chloro-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
4-bromo-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
4-chloro-benzoic acid 3-hydroxyl-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
2,6-dichlorobenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazono-methyl]-phenol,
4-methoxybenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
3-bromo-benzoic acid 4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
3-bromo-benzoic acid 4-[(4,6-two (4-anisole amino)-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester,
N-{4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-and the hydrazine methene] phenyl }-the 3-brombenzamide,
N '-(2, the 4-dihydroxy phenyl)-N-(4-morpholine-6-anilino-1,3,5-triazines-2-yl) first miaow,
Phenylformic acid 3-methoxyl group-4-((4-morpholine-6-anilino-1,3,5-triazines-2-base is amino) methene amido) phenyl ester,
4-(2-(4-morpholine-6-anilino-1,3,5-triazines-2-yl) acetal amino)-1, the 3-dihydroxy-benzene,
Phenylformic acid 3-methoxyl group-4-(2-(4-morpholine-6-anilino-1,3,5-triazines-2-yl) acetal amino) phenyl ester,
4-(2-(4-morpholine-6-anilino-1,3,5-triazines-2-base is amino) vinyl)-1, the 3-dihydroxy-benzene,
Phenylformic acid 3-methoxyl group-4-((4-morpholine-6-anilino-1,3,5-triazines-2-base is amino) vinyl) phenyl ester,
4-(3-(4-morpholine-6-anilino-1,3,5-triazines-2-yl) third-1-thiazolinyl)-1, the 3-dihydroxy-benzene,
Phenylformic acid 3-methoxyl group-4-(2-(4-morpholine-6-anilino-1,3,5-triazines-2-yl) third-1-thiazolinyl) phenyl ester,
4-(((4-morpholine-6-anilino-1,3,5-triazines-2-yl) methyl-imino) methyl)-1, the 3-dihydroxy-benzene, or
Phenylformic acid 3-methoxyl group-4-(((4-morpholine-6-(anilino)-1,3,5-triazines-2-yl) methyl-imino) methyl) phenyl ester.
The I that the formula Compound I of the invention provides comprises
A, I
B, I
C, I
D, and I
EThe preparation method of compounds and intermediate II thereof, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX.R wherein
1, R
2, R
3, R
4, R
5, R
6With the definition of Y as mentioned above.
I
AThe synthetic of compounds is with 2,4, and 6-three chloro-[1,3,5] triazine is a raw material, replaces through monoamine respectively, and two ammonia replace, and hydrazine replaces, and Y-replaces and condensation reaction makes.Synthesis strategy is embodied in the graphic scheme 1.
Scheme 12,4-disubstituted amido-6-replaces diazanyl-[1,3,5] compound in triazine class I
APreparation
I
BThe synthetic of compounds is with 2,4,6-three chloro-1, and the 3-pyrimidine is a raw material, replaces through monoamine respectively, (reaction conditions is than I in two ammonia replacements
AHarsh), hydrazine replaces, and Y-replaces and condensation reaction makes.Synthesis strategy is embodied in the graphic scheme 2.
Scheme 22,4-disubstituted amido-6-replaces diazanyl-1,3-pyrimidines I
BPreparation
I
CCompounds synthetic is to be raw material with N-Boc-2-(4,6-two chloro-[1,3,5] triazine-2 base) methylamine, replaces through monoamine respectively, and two ammonia replace, and take off the Boc-protecting group, and Y-replaces and condensation reaction makes.Synthesis strategy is embodied in the graphic scheme 3.
Scheme 32,4-disubstituted amido-6-replacement-[1,3,5] compound in triazine class I
CPreparation
I
DThe synthetic of compounds is with 2-Boc-amino-4, and 6-two chloro-[1,3,5] triazine is a raw material, replaces through monoamine respectively, and two ammonia replace, and take off the Boc-protecting group, and Y-replaces and condensation reaction makes.Synthesis strategy is embodied in the graphic scheme 4.
Scheme 42,4-disubstituted amido-6-replacement-[1,3,5] compound in triazine class I
DPreparation
I
EThe synthetic of compounds is that 6-two chloro-1,3,5-triazines are raw material with 2-((1,3-dimercapto-2-yl) methyl)-4, replaces through monoamine respectively, and two ammonia replace, and take off 1,3-dimercapto protecting group, and Y-replaces and condensation reaction makes.Synthesis strategy is embodied in the graphic scheme 5.
Scheme 52,4-disubstituted amido-6-replacement-[1,3,5] compound in triazine class I
EPreparation
Preparation formula I
A2 of expression, the method for 4-disubstituted amido-6-replacement-[1,3,5] compound in triazine class, this method may further comprise the steps:
1) 4,6-two chloro-[1,3,5] triazine-2-base-N-substitutional amine-group compound II's is synthetic:
To 2,4, add the replacement amine and the alkali of equivalent in the acetone soln of 6-three chloro-[1,3,5] triazine, ice bath stirred 2-48 hour; In the big water gaging of reaction solution impouring, stirred 30 minutes, separate out a large amount of solids, suction filtration, washing, the dry product II that gets;
Synthesis strategy is as follows:
2) 2-replacement-6-chloro-N
4-replacement-[1,3,5] triazine-diamine compounds III's is synthetic:
To 4, add the replacement amine and the alkali of equivalent in the dioxane solution of 6-two chloro-[1,3,5] triazine-2-base-N-substitutional amine-group compound II, ice bath stirred 2～48 hours; In the big water gaging of reaction solution impouring, stirred 30 minutes, separate out a large amount of solids, suction filtration, washing, the dry product III that gets;
Synthesis strategy is as follows:
3) 2,4,6-three replacement-[1,3,5] triazine-diamine compounds IV's is synthetic:
With 2-replacement-6-chloro-N
4-replacement-[1,3,5] triazine-diamine compounds III and excessive hydrazine hydrate reaction reflux and stirred 3～24 hours, are chilled to room temperature, suction filtration, and drying gets product IV;
Synthesis strategy is as follows:
4) Y
4-replacement-R
2Replace the synthetic of compounds V:
Under alkaline condition, 20～70 ℃ of temperature controls stirred 5～24 hours with aldehyde or the amine of protecting and excessive carboxylic acid halides/alkane halogen, and in the big water gaging of reaction solution impouring, organic solvent extraction is used pickling, alkali cleaning, washing successively, and drying is filtered, and removes solvent under reduced pressure and gets product V;
Synthesis strategy is as follows:
5) Compound I
ASynthetic:
Compound IV and V refluxed in alcohol 2～24 hours, and the small amount of acid catalyzed reaction is chilled to room temperature, suction filtration, and drying gets product I
A
Synthesis strategy is as follows:
Used alkali is mineral alkali or organic bases in the above steps, and described mineral alkali is selected from yellow soda ash, salt of wormwood, sodium hydroxide and the sodium bicarbonate, and described organic bases is selected from triethylamine, diethylamine and the pyridine; Step 1) or 3) acetone or dioxane solvent used in are interchangeable, also replaceable one-tenth methyl alcohol, THF, propyl alcohol or Virahol; Used acid is Glacial acetic acid, hydrochloric acid, sulfuric acid or phosphoric acid in the step 5).
Preparation formula I
C2 of expression, the method for 4-disubstituted amido-6-replacement-[1,3,5] compound in triazine class is characterized in that this method may further comprise the steps:
1) N-Boc-2-(6-chloro-N
4-replacement-[1,3,5] triazine-2 base) methylamines IX's is synthetic:
Add the replacement amine and the alkali of equivalent in the dioxane solution of N-Boc-2-(4,6-two chloro-[1,3,5] triazine-2 base) methylamine, ice bath stirred 2～48 hours; In the big water gaging of reaction solution impouring, stirred 30 minutes, separate out a large amount of solids, suction filtration, washing, the dry product IX that gets;
Synthesis strategy is as follows:
2) 2,4,6-three replacement-[1,3,5] triazine-diamine compounds XI's is synthetic:
With N-Boc-2-(6-chloro-N
4-replacement-[1,3,5] triazine-2 base) methylamines IX and excessive replacement amine reaction reflux and stirred 3～24 hours, are chilled to room temperature, suction filtration, and drying gets product X, and X gets product X I through sloughing Boc again;
Synthesis strategy is as follows:
3) Y
4-replacement-R
2Replace the synthetic of compounds V:
Under alkaline condition, 20～70 ℃ of temperature controls stirred 5～24 hours with aldehyde or the amine of protecting and excessive carboxylic acid halides/alkane halogen, and in the big water gaging of reaction solution impouring, organic solvent extraction is used pickling, alkali cleaning, washing successively, and drying is filtered, and removes solvent under reduced pressure and gets product V;
Synthesis strategy is as follows:
4) Compound I
CSynthetic:
Compounds X I and V refluxed in alcohol 2～24 hours, and the small amount of acid catalyzed reaction is chilled to room temperature, suction filtration, and drying gets product I
C
Synthesis strategy is as follows:
Used alkali is mineral alkali or organic bases in the above steps, and described mineral alkali is selected from yellow soda ash, salt of wormwood, sodium hydroxide and the sodium bicarbonate, and described organic bases is selected from triethylamine, diethylamine and the pyridine; Used acid is Glacial acetic acid, hydrochloric acid, sulfuric acid or phosphoric acid in the step 4).
At preparation formula I
AOr formula I
C2 of expression, in the method for 4-disubstituted amido-6-replacement-[1,3,5] compound in triazine class, each goes on foot products therefrom and can purify respectively, obtains pure products, and wherein the method for Ti Chuning comprises column chromatography or recrystallization.
Another aspect of the present invention relates to the pharmaceutical composition that prevents and/or treats the HIV virus infection, described pharmaceutical composition contains shown in the formula (I) 2,4-disubstituted amido-6-replaces-[1,3,5] triazine or 1,3-pyrimidines or its pharmacy acceptable salt and at least a pharmaceutically acceptable carrier, it can be used for interior therapeutic and has biocompatibility.Described pharmaceutical composition can be prepared into various forms according to different way of administration.Pharmaceutical composition of the present invention can be used to prevent and/or treat the HIV virus infection.
Medicinal compositions provided by the present invention can be a various ways, as tablet, capsule, powder, syrup, solution shape, suspension and aerosol etc., and may reside in suitable solid or liquid support or the diluent and the suitable disinfector injecting or instil of being used for.This medicinal compositions also can comprise odorant agent, flavouring agent etc., its ideal ratio is, formula (I) compound accounts for gross weight than more than 65% as activeconstituents, rest part is for accounting for gross weight than 0.5～40%, or more preferably 1～20%, or be preferably 1～10% pharmaceutically acceptable carrier, diluent or solution or salts solution.
The compound of aforesaid structural formula (I) can comprise humans and animals to the clinical use of Mammals, can through port, the route of administration of nose, skin, lung or gi tract etc.The best is preferably oral.Best preferred per daily dose is 0.01～200mg/kg body weight, disposable taking, or 0.01～100mg/kg body weight part vic.Which kind of instructions of taking that don't work, individual's optimal dose should be decided according to concrete treatment.Generally be from low dose, increase dosage gradually until find optimal dosage.
Formula (I) compound is integrated into the process of host chromosome by the HIV double chain DNA molecule that blocking-up IN participates in, thereby plays the effect that suppresses virus replication.Be used for the treatment of HIV virus infection.
Description of drawings
Fig. 1 is for detecting the proteic electrophorogram of purifying;
Fig. 2 is IA-3 and the dynamic analysis of HIV-1 intergrase;
Fig. 3 is the mensuration of the IC50 value of IA-3.
Embodiment
In following embodiment, will further illustrate the present invention.These embodiment only are used to illustrate the present invention, but do not limit the present invention in any way.All parameters among the embodiment and remaining explanation unless otherwise indicated, all are the explanation foundation with the quality.
Embodiment 1
4,6-two chloro-[1,3,5] triazine-2-base aniline (II-1)
With 2.0 grams 2,4,6-three chloro-[1,3,5] triazine is dissolved in 12 milliliters of dioxane, under the ice bath cooling and stirring, slowly drips the acetone soln (/ 2 milliliters of 1 grams) of aniline.After dropwising, disposable adding 1.16 gram yellow soda ash continue ice bath and stir after 5 hours, are warming up to stirring at room 2 hours.In reaction solution, drip in 150 ml waters, stirred 30 minutes, separate out a large amount of solids, suction filtration, washing, dry that light yellow solid product 2.48 restrains yield 95.4%.Mp?132-133℃(lit.133-135℃)。MS-EI?240(M+，100％)。
Embodiment 2
(4-chloro-6-morpholine-4-base-[1,3,5] triazine-2-yl) aniline (III-1)
1.0 gram II-1 are dissolved in 6 milliliters of dioxane, under the ice bath cooling and stirring, slowly drip the acetone soln (/ 1 milliliter of 0.36 gram) of morpholine.After dropwising, disposable adding 0.438 gram yellow soda ash continues ice bath and stirs after 2 hours, is warming up to stirring at room 1 hour.In reaction solution, drip in 70 ml waters, stirred 30 minutes, separate out a large amount of solids, suction filtration, washing, dry that light yellow solid product 1.06 restrains yield 88.0%.Mp?193-195℃(lit.198.5-199.5℃)。1H-NMR(400Hz，CDCl3)δ：3.75(4H，m)，3.85(4H，m)，7.14(1H，t)，7.18(1H，br)，7.38(2H，t)，7.52(2H，t)。
Embodiment 3
(4-diazanyl-6-morpholine-4-base-[1,3,5] triazine-2-yl) aniline (IV-1)
0.5 gram III-1 is put in 15 milliliter 85% the hydrazine hydrate, refluxes and stirred 2 hours, be chilled to room temperature, pumping rate, a small amount of dehydrated alcohol is washed, off-white color solid 0.4 gram, yield 81.6%.Mp?170-171℃；MS-EI?287(M+，100％)。
Phenylformic acid-3-methoxyl group-4-formyl radical-phenyl ester (V-1)
0.2 gram 2-methoxyl group-4-hydroxyl-phenyl aldehyde is dissolved in 5 milliliters of anhydrous pyridines, under the stirring at room, drips 0.36 gram Benzoyl chloride, finished stirring at room 12 hours, in reaction solution impouring 50 ml waters, ethyl acetate extracts (30mlx3), merges organic layer, dilute acid solution is given a baby a bath on the third day after its birth inferior, aqueous sodium carbonate is washed once, and anhydrous magnesium sulfate drying filters, remove solvent under reduced pressure and get light yellow solid 0.16 gram, yield 48.5%.1H-NMR(400Hz，CDCl3)δ：3.95(3H，s)，6.93(2H，m)，7.56(2H，t)，7.67(1H，d)，7.94(1H，d)，8.22(2H，d)，10.44(1H，s)。
4-(3-bromo-benzyloxy-)-2-methoxyl group-phenyl aldehyde (V-2)
With 0.88 gram 3-bromobenzyl chlorine, 0.5 gram 4-hydroxyl-2-methoxybenzaldehyde and 0.59 gram salt of wormwood are put in 10 milliliters of acetone, reflux and stir 12 hours, be chilled to room temperature, add 50 ml waters, ethyl acetate extracts, column chromatography for separation gets white solid 0.46 gram, Mp 101-103 ℃, yield 43.6%.
1H-NMR(400Hz，CDCl
3)δ：3.90(3H，s)，5.10(2H，s)，6.54(2H，s)，7.30(1H，t)，7.36(1H，d)，7.50(1H，d)，7.61(1H，s)，7.83(1H，d)，10.30(1H，s)。MS-EI?320(M
+)，169(100％)。
Phenylformic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-1)
128 milligrams of V-1 and 144 milligrams of IV-1 are put in 25 milliliters of dehydrated alcohols, add 2 Glacial acetic acid, stirring and refluxing 2 hours is chilled to room temperature, pumping rate, and small amount of ethanol is washed, and gets white solid I
A-1145 milligrams, Mp 211-213 ℃, yield 55.3%.
1H-NMR(，400Hz，DMSO-d6)δ：3.66(4H，m)，3.75(4H，m)，3.85(3H，s)，7.00(2H，m)，7.09(1H，s)，7.30(2H，t)，7.65(2H，t)，7.74-7.85(3H，m)，7.95(1H，d)，8.16(2H，d)，8.46(1H，s)。MS-EI?525(M
+)，271(100％)。
(4-{N '-[4-(3-the bromo-benzyloxy-)-rare base of 2-methoxyl group-benzyl]-diazanyl }-6-morpholine-4-base-[1,3,5]-triazine-2-yl)-aniline (I
A-2)
V-1 is replaced to V-2, and all the other desired raw materials, reagent and preparation method get white solid I with embodiment 6
A-2187 milligrams, Mp 185-186 ℃, yield 63.4%.
1H-NMR(400Hz，DMSO-d6)δ：3.67(4H，m)，3.75(4H，m)，3.84(3H，s)，5.19(2H，s)，6.73(2H，s)，6.98(1H，t)，7.30(2H，t)，7.41(1H，t)，7.51(1H，d)，7.58(1H，d)，7.70(1H，s)，7.78-7.79(3H，m)，8.39(1H，s)。MS-EI?589(M
+)，271(100％)。
3-bromo-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-3)
Benzoyl chloride is replaced to the 3-bromo-benzoyl chloride, and all the other desired raw materials, reagent and preparation method get white solid I with embodiment 4 and 6
A-3270 milligrams, Mp 175-177 ℃, yield 89.4%.
1H-NMR(400Hz，DMSO-d6)δ：3.66(4H，m)，3.74(4H，m)，3.84(3H，s)，6.92-7.01(2H，m)，7.12(1H，s)，7.29(2H，t)，7.62(1H，t)，7.82(2H，br)，7.99(2H，m)，8.15(1H，d)，8.26(1H，s)，8.45(1H，s)。MS-EI?603(M
+)，271(100％)。
4-trifluoromethylbenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-4)
Benzoyl chloride is replaced to the 4-trifluoromethyl benzoyl chloride, and all the other desired raw materials, reagent and preparation method get white solid I with embodiment 4 and 6
A-4135 milligrams, Mp 234-236 ℃, yield 67.2%.
1H-NMR(400Hz，DMSO-d6)δ：3.65(4H，m)，3.75(4H，m)，3.85(3H，s)，6.92-7.03(2H，m)，7.12(1H，s)，7.29(2H，t)，7.82(2H，br)，7.95(1H，d)，8.01(2H，d)，8.36(2H，d)，8.46(1H，s)。MS-EI?593(M
+)，271(100％)。
4-toluene sulfonic acide acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-5)
Benzoyl chloride is replaced to 4-Methyl benzenesulfonyl chlorine, and all the other desired raw materials, reagent and preparation method get white solid I with embodiment 4 and 6
A-5 240 milligrams, Mp 239-241 ℃, yield 83.6%.
1H-NMR(400Hz，DMSO-d6)δ：2.41(3H，s)，3.65(4H，m)，3.75(7H，m)，6.64-6.70(2H，m)，6.97(1H，t)，7.28(2H，t)，7.50(2H，d)，7.79(5H，m)，8.35(1H，s)。MS-EI?575(M
+)，271(100％)。
Embodiment 11
3-bromo-benzoic acid 2-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-6)
2-methoxyl group-4-hydroxy benzaldehyde is replaced to 3-methoxyl group-4-hydroxy benzaldehyde, and all the other desired raw materials, reagent and preparation method get white solid I with embodiment 4 and 6
A-6173 milligrams, Mp 142-144 ℃, yield 79.0%.
1H-NMR(400Hz，DMSO-d6)δ：3.66(4H，m)，3.75(4H，m)，3.84(3H，s)，6.97(1H，t)，7.29(2H，t)，7.33(2H，s)，7.48(1H，s)，7.62(1H，t)，7.81(2H，br)，7.99(1H，d)，8.15(2H，d)，8.22(1H，s)。MS-EI?603(M
+)，271(100％)。
Embodiment 12
3-bromo-benzoic acid 2-oxyethyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-7)
2-methoxyl group-4-hydroxy benzaldehyde is replaced to vanirom, and all the other desired raw materials, reagent and preparation method get light yellow solid I with embodiment 4 and 6
A-7240 milligrams, Mp 118-119 ℃, yield 77.7%.
1H-NMR(400Hz，DMSO-d6)δ：1.28(3H，t)，3.66(4H，m)，3.75(4H，m)，4.14(2H，q)，6.98(1H，t)，7.29(2H，t)，7.33(2H，s)，7.47(1H，s)，7.62(1H，t)，7.81(2H，br)，7.99(1H，d)，8.14(2H，d)，8.23(1H，s)。MS-EI?617(M
+)，271(100％)。
Embodiment 13
3-bromo-benzoic acid 3-methoxyl group-4-{[4-phenylamino-6-(4-sulfamyl phenylamino)-[1,3,5] triazine-2-yl]-the hydrazine methene }-phenyl ester (I
A-8)
With aniline, morpholine and Benzoyl chloride replace to sulfanilamide (SN) respectively, aniline and 3-bromo-benzoyl chloride, and all the other desired raw materials, reagent and preparation method get off-white color solid I with embodiment 1-4 and 6
A-8157 milligrams, Mp 218-220 ℃, yield 76.2%.
1H-NMR(400Hz，DMSO-d6)δ：3.87(3H，s)，7.05(2H，m)，7.15(1H，d)，7.35(2H，t)，7.63(1H，t)，7.73(2H，d)，7.85(2H，br)，7.99(2H，m)，8.06(2H，br)，8.16(1H，d)，8.27(1H，t)，8.54(1H，s)。MS-ESI?689[M+H]
+。
Embodiment 14
4-chloro-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-9)
Benzoyl chloride is replaced to the 4-chloro-benzoyl chloride, and all the other desired raw materials, reagent and preparation method get white solid I with embodiment 4 and 6
A-9250 milligrams, Mp 211-212 ℃, yield 86.6%.
1H-NMR(400Hz，DMSO-d6)δ：3.66(4H，m)，3.74(4H，m)，3.85(3H，s)，7.00(2H，m)，7.10(1H，s)，7.29(2H，t)，7.71(2H，d)，7.81(2H，br)，7.94(1H，d)，8.16(2H，d)，8.45(1H，s)。MS-EI?559(M
+)，271(100％)。
4-bromo-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-10).
Benzoyl chloride is replaced to the 3-bromo-benzoyl chloride, and all the other desired raw materials, reagent and preparation method get 4-bromo-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 4 and 6)-the hydrazine methene]-phenyl ester.
Embodiment 16
4-methoxybenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-11)
Benzoyl chloride is replaced to the 4-methoxy benzoyl chloride, and all the other desired raw materials, reagent and preparation method get 4-methoxybenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 4 and 6)-the hydrazine methene]-phenyl ester.
Embodiment 17
2-chloro-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-12)
Benzoyl chloride is replaced to the 2-chloro-benzoyl chloride, and all the other desired raw materials, reagent and preparation method get 2-chloro-benzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 4 and 6)-the hydrazine methene]-phenyl ester.
Embodiment 18
2,6-dichlorobenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-13)
Benzoyl chloride is replaced to 2, the 6-dichlorobenzoyl chloride, all the other desired raw materials, reagent and preparation method get 2,6-dichlorobenzoic acid 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 4 and 6)-the hydrazine methene]-phenyl ester.
Embodiment 19
3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenol (I
A-14)
V-1 is replaced to 2-methoxyl group-4-hydroxyl-phenyl aldehyde, and all the other desired raw materials, reagent and preparation method get 3-methoxyl group-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 6)-the hydrazine methene]-phenol.
3-bromo-benzoic acid 4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-15)
2-methoxyl group-4-hydroxyl-phenyl aldehyde is replaced to 4-hydroxyl-phenyl aldehyde, with Benzoyl chloride replace to the 3-bromo-benzoyl chloride with all the other desired raw materials, reagent and preparation method with embodiment 4 and 6, get 3-bromo-benzoic acid 4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester.
Embodiment 21
4-chloro-benzoic acid 3-hydroxyl-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-16)
2-methoxyl group-4-hydroxyl-phenyl aldehyde is replaced to 2,4-dihydroxyl-phenyl aldehyde, with Benzoyl chloride replace to the 4-chloro-benzoyl chloride with all the other desired raw materials, reagent and preparation method with embodiment 4 and 6, get 4-chloro-benzoic acid 3-hydroxyl-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester.
Embodiment 22
4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-and the hydrazono-methyl]-1,3-dihydroxy-benzene (I
A-17)
V-1 is replaced to 2,4-dihydroxyl-phenyl aldehyde, all the other desired raw materials, reagent and preparation method get 4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 6)-the hydrazono-methyl]-1, the 3-dihydroxy-benzene.1H-NMR(300Hz，d6-DMSO)δ3.64(m，4H)，3.74(m，4H)，6.34(d，s，2H)，6.96(m，1H)，7.16(d，1H，J＝8.1Hz)，7.27(m，2H)，7.75(br，2H)，8.17(s，1H)。MS-EI?m/z：407(M
+)。HR?EI-MS：Calcd.forC
20H
21N
7O
3：407.1706；Found：407.1715。
Embodiment 23
3-bromo-benzoic acid 4-[(4,6-two (4-anisole amino)-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-18)
With aniline, morpholine and Benzoyl chloride replace to 4-anisidine and 3-bromo-benzoyl chloride respectively, and all the other desired raw materials, reagent and preparation method are with embodiment 1-4 and 6, get 3-bromo-benzoic acid 4-[(4,6-two (4-anisole amino)-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester.
Embodiment 24
2-acetoxy-benzoic acid 3-(2-acetoxyl group benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-19)
The acetylsalicylic acid of 99mg (0.55mmol) is suspended in the exsiccant CH of 5mL
2Cl
2, ice bath adds the oxalyl chloride of the new steaming of 55 μ L (0.61mmol) down, adds a DMF catalyzed reaction, changes stirring at room 4-5h behind the 10min; Then, ice bath directly adds (the I of 100mg down
A-17) (0.25mmol), stir 10min after, slowly add TEA and be weakly alkaline to solution, continue reaction 1h, the CH of adding 20mL in the solution
2Cl
2, washing is (10ml) once, and saturated NaCl washes once (10ml), anhydrous Na
2SO
4Drying is drained, and obtains the 185mg crude product, and the chromatographic column purifying obtains 165mg 2-acetoxy-benzoic acid 3-(2-acetoxyl group benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-19), yield 91.7%, Mp 99-101 ℃.
1H-NMR(300Hz，CDCl
3)δ2.29(s，3H)，2.33(s，3H)，3.74(m，4H)，3.83(m，4H)，7.05(t，1H，J＝7.5Hz)，7.13(m，2H)，7.20(m，3H)，7.32(t，2H，J＝7.5Hz，)，7.42(q，2H，J＝7.8Hz)，7.59-7.71(m，4H)，7.91(s，1H)，8.23(t，2H，J＝7.8Hz)；MS-EI?m/z：731(M
+)。
4-pivaloyl aminobenzoic acid 3-(4-pivaloyl oxygen base benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-20)
Acetylsalicylic acid is replaced to 4-pivaloyl aminobenzoic acid, all the other desired raw materials, reagent and preparation method are with embodiment 24, get 176mg 4-pivaloyl aminobenzoic acid 3-(4-pivaloyl oxygen base benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-20), yield 96.2%.
1H-NMR(300Hz，CDCl
3)δ1.36(s，18H)，3.72(m，4H)，3.80(m，4H)，7.04(t，1H，J＝7.8Hz)，7.15-7.32(m，9H)，7.35(m，2H)，7.98(s，1H)，8.18-8.26(m，4H)；MS-EIm/z：815(M
+)。
Embodiment 26
Phenylformic acid 3-benzoyloxy-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-21)
Acetylsalicylic acid is replaced to phenylformic acid, and all the other desired raw materials, reagent and preparation method get phenylformic acid 3-benzoyloxy-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl with embodiment 24)-the hydrazine methene]-phenyl ester.
Embodiment 27
2 hydroxybenzoic acid 3-(2-(2-hydroxybenzoyl) oxygen base)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-22)
Acetylsalicylic acid is replaced to 2 hydroxybenzoic acid, all the other desired raw materials, reagent and preparation method are with embodiment 24, get phenylformic acid 2 hydroxybenzoic acid 3-(2-(2-hydroxybenzoyl) oxygen base)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester.
Embodiment 28
2-benzaminic acid 3-(2-aminobenzoic acyl-oxygen base)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-23)
Acetylsalicylic acid is replaced to the 2-benzaminic acid, all the other desired raw materials, reagent and preparation method are with embodiment 24, get phenylformic acid 2-benzaminic acid 3-(2-aminobenzoic acyl-oxygen base)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester.
Embodiment 29
2-acetylamino benzoic acid 3-(2-kharophen benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester (I
A-24)
Acetylsalicylic acid is replaced to the 2-acetylamino benzoic acid, all the other desired raw materials, reagent and preparation method are with embodiment 24, get 2-acetylamino benzoic acid 3-(2-kharophen benzoyloxy)-4-[(4-morpholine-4-base-6-phenylamino-[1,3,5] triazine-2-yl)-the hydrazine methene]-phenyl ester.
Embodiment 30
(2,6-dichloro pyrimidine-4-yl)-(4-p-methoxy-phenyl) amine (VI-1)
With 2,4,6-trichloropyrimidine 2.36 grams, 4-anisidine 3.17 grams and yellow soda ash 1.36 grams are put in 20 milliliters of ethanol, reflux and stir 2 hours.Be chilled to room temperature, add 70 ml waters, pumping rate obtains to such an extent that thick product gets white solid 2.4 grams, Mp158-160 ℃ (lit.160-162 ℃), yield 69.4% with 75% aqueous ethanolic solution recrystallization.
1H-NMR(400Hz，CDCl
3)δ：3.84(3H，s)，6.37(1H，s)，6.98(2H，d)，7.26(2H，d)，7.37(1H，br)。
Embodiment 31
6-chloro-N
4-(4-p-methoxy-phenyl)-N
2-phenyl-pyrimidine-2,4-diamines (VII-1)
With the VI-11.2 gram, aniline 3.17 grams and yellow soda ash 1.2 grams are put in 20 milliliters of dioxane, reflux and stir 48 hours.Be chilled to room temperature, add 70 ml waters, dichloromethane extraction, drying concentrates, and the resistates column chromatography for separation gets off-white color solid phase prod 0.8 gram, and Mp 102-105 ℃, yield 55.2%.MS-EI?326(M
+)，269(100％)。
Embodiment 32
6-diazanyl-N
4-(4-p-methoxy-phenyl)-N
2-phenyl-pyrimidine-2,4-diamines (VIII-1)
VII-20.3 is restrained in the hydrazine hydrate of putting into 10 milliliter 85%, and stirring and refluxing 2 hours is chilled to room temperature, and pumping rate gets off-white color solid product 0.23 gram.Mp 173-174 ℃, yield 77.7%.MS-EI?322(M
+，100％)。
Embodiment 33
3-bromo-benzoic acid 3-methoxyl group-4-{[6-(4-anisole amido)-2-anilino-pyrimidine-4-yl]-the hydrazine methene }-phenyl ester (I
B-1)
With Benzoyl chloride, IV-1 replaces to the 3-bromo-benzoyl chloride respectively, VIII-1, and all the other desired raw materials, reagent and preparation method get off-white color solid I with embodiment 4 and 6
B-1105 milligrams, Mp 187-188 ℃, yield 55.0%.
1H-NMR(400Hz，DMSO-d6)δ：3.74(3H，s)，3.87(3H，s)，6.04(1H，s)，6.92(3H，m)，7.02(1H，d)，7.14(1H，s)，7.27(2H，t)，7.57-7.64(3H，m)，7.83(2H，d)，7.91(1H，d)，8.00(1H，d)，8.17(1H，d)，8.28(1H，s)，8.42(1H，s)。MS-EI?602(M
+)，270(100％)。
Embodiment 34
N-Boc-2-(4-anilino-6-chloro-[1,3,5] triazine-2 base) methylamine (IX-1)
With 2,4,6-three chloro-[1,3,5] triazine replaces to N-Boc-2-(4,6-two chloro-[1,3,5] triazine-2 base) methylamine, and all the other desired raw materials, reagent and preparation method get N-Boc-2-(4-anilino-6-chloro-[1,3,5] triazine-2 base) methylamine with embodiment 1.
Embodiment 35
N-Boc-2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine (X-1)
With 4,6-two chloro-[1,3,5] triazine-2-base aniline replaces to N-Boc-2-(4-anilino-6-chloro-[1,3,5] methylamine triazine-2 base), all the other desired raw materials, reagent and preparation method are with embodiment 2, get N-Boc-2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine.
Embodiment 36
2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine (XI-1)
With 0.5 gram N-Boc-2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine is dissolved in 20 milliliters of 20% trifluoroacetic acids/dry methylene chloride solution, after the normal-temperature reaction 2 hours, solid is collected in underpressure distillation, washing repeatedly, get 2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine.
Embodiment 37
Phenylformic acid 3-methoxyl group-4-(((4-morpholine-6-(anilino)-1,3,5-triazines-2-yl) methyl-imino) methyl) benzene fat (I
C-1)
With (4-diazanyl-6-morpholine-4-base-[1,3,5] triazine-2-yl) aniline replaces to 2-(4-anilino-6-morpholine-[1,3,5] methylamine triazine-2 base), all the other desired raw materials, reagent and preparation method get phenylformic acid 3-methoxyl group-4-(((4-morpholine-6-(anilino)-1 with embodiment 6,3,5-triazine-2-yl) methyl-imino) methyl) benzene fat.
Embodiment 38
2-Boc-amino-4-anilino-6-chloro-[1,3,5] triazines (XII-1)
With 2,4,6-three chloro-[1,3,5] triazine replaces to 2-Boc-amino-4, and 6-two chloro-[1,3,5] triazine, all the other desired raw materials, reagent and preparation method get 2-Boc-amino-4-anilino-6-chloro-[1,3,5] triazine with embodiment 1.
Embodiment 39
2-Boc-amino-4-anilino-6-morpholine-[1,3,5] triazines (XIII-1)
With 4,6-two chloro-[1,3,5] triazine-2-base aniline replaces to 2-Boc-amino-4-anilino-6-chloro-[1,3,5] triazine, and all the other desired raw materials, reagent and preparation method get 2-Boc-amino-4-anilino-6-morpholine-[1,3,5] triazine with embodiment 2.
Embodiment 40
2-amino-4-anilino-6-morpholine-[1,3,5] triazines (XIV-1)
N-Boc-2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine is replaced to 2-Boc-amino-4-anilino-6-morpholine-[1,3,5] triazine, all the other desired raw materials, reagent and preparation method are with embodiment 36, get 2-amino-4-anilino-6-morpholine-[1,3,5] triazine.
Embodiment 41
Phenylformic acid-3-methoxyl group-4-(N-Boc amino)-phenyl ester (XV-1)
2-methoxyl group-4-hydroxyl-phenyl aldehyde is replaced to 2-methoxyl group-4-hydroxy-n-Boc-aniline, and all the other desired raw materials, reagent and preparation method get phenylformic acid-3-methoxyl group-4-(N-Boc amino)-phenyl ester with embodiment 4.
Embodiment 42
Phenylformic acid-3-methoxyl group-4-amino-phenyl ester (XVI-1)
With N-Boc-2-(4-anilino-6-morpholine-[1,3,5] triazine-2 base) methylamine replaces to phenylformic acid-3-methoxyl group-4-(N-Boc amino)-phenyl ester, and all the other desired raw materials, reagent and preparation method get phenylformic acid-3-methoxyl group-4-amino-phenyl ester with embodiment 36.
Embodiment 43
Phenylformic acid 3-methoxyl group-4-((4-morpholine-6-anilino-1,3,5-triazines-2-base is amino) methene amido) phenyl ester (ID-1)
100 milligrams of IXV-1 and 1 equivalent XVI-1 are dissolved in an amount of tetrahydrofuran (THF), add monovalent formaldehyde, stirring at room, underpressure distillation after reaction is finished, column chromatography gets compound phenylformic acid 3-methoxyl group-4-((4-morpholine-6-anilino-1,3,5-triazines-2-base is amino) methene amido) phenyl ester.
Embodiment 44
2-((1,3-dimercapto-2-yl) methyl)-4-anilino-6-chloro-1,3,5-triazines (XVII-1)
With 2,4,6-three chloro-[1,3,5] triazine replaces to 2-((1,3-dimercapto-2-yl) methyl)-4,6-two chloro-1,3,5-triazines, all the other desired raw materials, reagent and preparation method are with embodiment 1, get 2-((1,3-dimercapto-2-yl) methyl)-4-anilino-6-chloro-1,3,5-triazines.
Embodiment 45
2-((1,3-dimercapto-2-yl) methyl)-4-anilino-6-morpholine-1,3,5-triazines (XVIII-1)
With 4,6-two chloro-[1,3,5] triazine-2-base aniline replaces to 2-((1,3-dimercapto-2-yl) methyl)-4-anilino-6-chloro-1,3, the 5-triazine, all the other desired raw materials, reagent and preparation method are with embodiment 2, get 2-((1,3-dimercapto-2-yl) methyl)-4-anilino-6-morpholine-1,3,5-triazines.
Embodiment 46
2-aldehyde-base-4-anilino-6-morpholine-1,3,5-triazines (XIX-1)
With 0.5 gram 2-((1,3-dimercapto-2-yl) methyl)-4-anilino-6-morpholine-1,3, the 5-triazine is dissolved in the proper amount of acetone, adds the cupric chloride of equivalent and the cupric oxide of equivalent, refluxes three hours, column chromatography gets product 2-aldehyde-base-4-anilino-6-morpholine-1,3,5-triazines.
Embodiment 47
Phenylformic acid 3-methoxyl group-4-(2-(4-morpholine-6-anilino-1,3,5-triazines-2-yl) acetal amino) phenyl ester (I
E-1)
With (4-diazanyl-6-morpholine-4-base-[1; 3; 5] triazine-2-yl) aniline and phenylformic acid-3-methoxyl group-4-formyl radical-phenyl ester replaces to 2-aldehyde-base-4-anilino-6-morpholine-1 respectively; 3; 5-triazine and phenylformic acid-3-methoxyl group-4-amino-phenyl ester, all the other desired raw materials, reagent and preparation method get phenylformic acid 3-methoxyl group-4-(2-(4-morpholine-6-anilino-1 with embodiment 6; 3,5-triazine-2-yl) acetal amino) phenyl ester.
Embodiment 48
The HIV-1 intergrase of GST mark (IN, the structure of fusion rotein plasmid pGEX-4T-1-IN (F185K) integrase):
(1) experimental technique:
1) with the dna fragmentation (gene order according to AF040373 (GENEBANK)) of round pcr from pUC18-IN plasmid acquisition IN.
Primer: FW:5 '-ata tgg atc ctt ttta gat gga ata gat-3 '
RV：5′-ata?tct?cga?gct?aat?cct?cat?cct?g-3′
94 ℃ of sex change 5min begin circulation then: 94 ℃ of 45s, and 55 ℃ of 45s, 72 ℃ of 1min30s repeat circulation, 72 ℃ of 10min then 29 times.
Adopt 1% agarose gel electrophoresis evaluation PCR product and reclaim the PCR fragment.
2) with IN PCR fragment cloning to carrier pGEX-4T-1: IN PCR product and pGEX-4T-1 carry out endonuclease reaction with BamHI and XhoI respectively; Reclaim test kit recovery enzyme with glue and cut product; Do ligation with the T4DNA ligase enzyme; The connection product is transformed into DH5 α competent cell and is coated on the flat board that contains penbritin (100mg/l); Cut and check order by enzyme and identify correct clone.
3) phenylalanine with 185 of HIV-1 intergrases is mutated into Methionin: this step adopts the point mutation test kit of Invitrogen company.
Mutant primer: FW:5 '-ggcagtattcatccacaataagaaaagaaaaggggggattgg-3 '
RV：5’-ccaatccccccttttcttttcttattgtggatgaatactgcc-3’
Determine to take place the cloned plasmids pGEX-4T-1-IN (F185K) of correct sudden change by checking order.
(2) experimental result
1) agarose gel electrophoresis evaluation enzyme is cut the result: two restriction enzyme sites of BamHI and XhoI are arranged on the multiple clone site of pGEX-4T-1 carrier, IN is cloned on the pGEX-4T-1 by these two sites, and correct enzyme is cut the result and cut out the about 900bp of fragment of IN itself and the about 4900bp of fragment of carrier;
2) sequencing result shows that clone's sequence is identical with AF040373 (GENEBANK), only in the 553-555 position of sequence by original " ttt " sport " aaa ", the amino acid that corresponds to 185 is mutated into Methionin by phenylalanine.
Embodiment 49
The expression and purification of the HIV-1 intergrase (GST-IN) of GST mark:
(1) experimental technique
1) plasmid pGEX-4T-1-IN (F185K) is changed among the expression strain BL21 (DE3), select the correct 37 ℃ of overnight shakings that are cloned in and be incubated at 10ml ammonia benzyl LB substratum (yeast extract 5g/L, Tryptones 10g/L and NaCl 10g/L, penbritin concentration is 100mg/L) in, be transferred in the fresh ammonia benzyl LB substratum by 1: 100, shaking culture is to OD
600When value is between the 0.6-0.8, adds IPTG and be 0.2mM and culture temperature is reduced to 25 ℃ of inducible proteins expressed 5-7 hour to final concentration.5, the centrifugal 10min of 000rpm collects bacterium, washes recentrifuge behind the bacterium with the PBS damping fluid is outstanding, and places-70 ℃ of refrigerators preservations stand-by the bacterium of collecting.
2) stand-by thalline hangs with 20ml PBS, the ultrasonication bacterium, and 15, get the cleer and peaceful good Glutathione Sepharose of PBS balance that used behind the centrifugal 30min of 000rpm
TMThe affine resin of 4B is at 4 ℃ of mixing 4hrs, pass pillar after, with 100-150ml PBS flush away foreign protein, use the IN of 50mM GSH wash-out GST mark at last.
3) specification sheets that provides according to Amersham Biosciences company of the protein solution of wash-out utilizes the further separation and purification of Hiload 16/60Superdex75 molecular sieve prepacked column, used solution is 10mM HEPES and 150mM NaCl, collects albumen and detects purity with SDS-PAGE.
(2) experimental result
8%SDS-PAGE also detects the albumen of purifying with coomassie brilliant blue staining: 282 amino acid of HIV-1 intergrase total length, add that size is the GST mark of 27kD, and whole fusion rotein size is about 60kD.As shown in Figure 1, left side swimming lane is marker, and the right then is the good albumen HIV-1 intergrase of purifying, can be clearly seen that the band at about 60kD place on the SDS-PAGE glue after the dyeing, judges that purity is greater than 95%.
Embodiment 50
Utilize biosensor Biacore 3000 to detect I
A-3 is active with combining of HIV-1 intergrase:
(1) experimental technique
1) HIV-1 intergrase that purifying is the good program of utilizing Biacore3000 to carry with the method for amino coupled is coupled on the CM5 chip.The Biacore3000 system running environment is HBS-EP damping fluid (3mM EDTA and 0.01%P20, pH 7.4 for 10mM HEPES, 150mM NaCl).
2) with the I of different concns
A-3 are made into HBS-EP damping fluid (the 10mM HEPES that contains 0.1%DMSO, 150mM NaCl, 3mM EDTA and 0.01%P20, pH 7.4) do dynamic analysis, draw the equilibrium dissociation constant K of this compound and HIV-1 intergrase with Biacore evaluation 3.2 software analysis
D
(2) experimental result
I
A-3 show the active K of the very high combination of HIV-1 intergrase
D=0.38 μ M (Fig. 2)
Embodiment 51
With the IC of biosensor assay PLK275 to the HIV-1 intergrase
50Value:
(1) experimental technique
1) substrate analogue with the HIV-1 intergrase is coupled on the biosensor SA chip:
Synthesize the substrate similar DNA according to the terminal substrate sequences Design of the viral DNA of HIV-1 intergrase, and add vitamin H (biotin) mark at 5 ' end.Sequence: biotin-5 '-GTGTGGAAAATCTCTAGGTGT-3 '.Utilize vitamin H and Streptomycin sulphate bonded principle to be coupled to the SA chip the biotin labeled DNA of synthetic band.
2) biosensor assay I
AThe IC of-3 pairs of HIV-1 intergrases
50Value:
The HIV-1 intergrase that purifying is good and the I of different concns
A-3 hatch after 1 hour on ice and to do dynamic analysis, because the compound competition in conjunction with the HIV-1 intergrase, makes the HIV-1 intergrase that the binding ability of substrate DNA analogue on the chip is descended, show as the decline of RU value.According to the RU value and the concentration mapping of the different concns correspondence of compound, draw the IC of compound with software Origin analysis
50Value.
(2) experimental result
Can see increase along with compound concentration by Fig. 3, the HIV-1 intergrase descends to the RU value of SA chip.According to the RU value and the concentration mapping of the different concns correspondence of compound, analyze with Origin and to draw Compound I
A-3 IC
50Value is 0.97 μ M.
12 external anti-HIV-1 activity of compound such as embodiment 52Xs2
1. material and method
(1) medicine and compound
Testing sample Xs2, Xs19, Xs32, Xs77, XsF2, XsF9, Xs274, Xs275, Xs276, Xs277, Xs278, Xs279 is provided by professor Shen Xu of Shanghai Pharmaceutical Inst., Chinese Academy of Sciences.Positive control compound Zidovodine (3 '-Azido-3 '-deoxythymidine, AZT) available from Sigma company.12 samples all are dissolved among the DMSO, and stock solution concentration is 25mg/ml, and condition of storage is :-20 ℃; AZT is dissolved in the RPMI-1640 perfect medium, 0.22 μ m membrane filtration degerming ,-20 ℃ of preservations after the packing.
(2) reagent and solution a. reagent
HEPES (N-2 (2-Hydroxyothyl) piperazine-N '-(2-ethanesufonic acid), MTT (3, (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), DMF (N, N '-Dimethyl formamine), penicillin (Penicillin), Vetstrep (Streptomycin sulfate), glutamine (Glutamine) are all available from Sigma company; (2-ME 2-Mercaptoethanol) is Bio-Rad company product to 2 mercapto ethanol.RPMI-1640 and newborn calf serum are Gibco company product.
B. substratum
The RPMI-1640 perfect medium contains 10% deactivation newborn calf serum, 2mM L-glutaminate, 10Mm HEPES, 50 μ M 2 mercapto ethanols, 100,000IU penicillin, 100 μ g/ml Streptomycin sulphates.
(3) cell and virus
The human T lymphocyte is C8166, MT4 cell and HIV-1 experiment strain HIV-1
IIIBBy Britain Medical Research Council, AIDS Reagent Project is so kind as to give.All cells and virus are all cultivated with the RPMI-1640 perfect medium that contains 10% calf serum.Prepare HIV-1 according to a conventional method
IIIB, titration also calculates viral TCID
50After the packing of virus stock solution, put-70 ℃ of preservations.The frozen according to a conventional method and recovery of cell and virus.
(4) HIV-1 infectious titration
HIV-1
IIIBPress Johnson﹠amp; The described method improvement of Byington carries out titration, is summarized as follows: the HIV-1 stock solution is done 4 times of dilutions on 96 orifice plates, and 10 gradients, 6 repeating holes of every gradient are provided with control wells 6 holes simultaneously.Every hole adds C8166 cell 50 μ l (4 * 10
5/ ml), every hole final volume is 200 μ l.37 ℃, 5%CO
2Cultivate.Added fresh RPMI-1640 perfect medium 100 μ l on the 3rd day, under inverted microscope, observed HIV-1 inductive cytopathic effect (Cytopathic effect in every hole on the 7th day, CPE), whether there is the formation of synplasm (Syncytium) to determine with every hole; Press Reed﹠amp; The Muench method is calculated the TCID of virus
50(50%Tissue culture infection dose).
(5) compound is to the toxicity test of C8166 cell
4 * 10
5/ ml C8166 cell suspension 100ul and different testing compound solution mixing establish three repeating holes.The control wells that does not contain compound, 37 ℃, 5%CO are set simultaneously
2Cultivated 3 days, and adopted the MTT colorimetry to detect cytotoxicity.The ELx800 microplate reader is measured the OD value, and the mensuration wavelength is 595nm, and reference wavelength is 630nm.Calculate CC
50Value (50%Cytotoxicconcentration), the compound concentration during promptly to 50% normal T lymphocyte series C8166 toxigenicity.
(6) compound H IV-1
IIIBThe inhibition experiment of cytopathogenic effect (CPE)
With 8 * 10
5/ ml C8166 cell 50ul/ hole is inoculated on the 96 porocyte culture plates that contain 100 μ l/ hole gradient doubling dilution compounds, adds the HIV-1 of 50 μ l then
IIIBThe dilution supernatant, 1300TCID
50/ hole.If 3 repeating holes.The normal cell control wells that does not contain compound is set simultaneously.The positive medicine contrast of AZT.37 ℃, 5%CO
2Cultivated 3 days, (100 *) count plasmodial formation under the inverted microscope.EC
50(50%Effective concentration) forms 50% o'clock compound concentration for suppressing synplasm.
(7) compound infects the provide protection experiment of MT4 cell to HIV-1
With 8 * 10
5/ ml MT4 cell 50ul/ hole is inoculated on the 96 porocyte culture plates that contain 100 μ l/ hole doubling dilution compounds, and half hole of culture plate adds the HIV-1 of 50 μ l
IIIBDilution (M.O.I.=006), second half hole adds 50 μ l substratum.2 repeating holes of each concentration gradient are provided with control wells and the blank hole that does not contain compound, 37 ℃, 5%CO simultaneously
2Cultivate, 100 μ l fresh cultures were added in every hole in the 3rd day, adopted the MTT colorimetry to detect cell survival rate in the 5th day or the 6th day.The ELx800ELISA instrument is measured the OD value, and the mensuration wavelength is 595nm, and reference wavelength is 630nm.Calculate compound to Normocellular toxicity with to HIV-1 with formula
IIIBThe provide protection of cells infected.
(8) calculation formula
Draw dose response curve according to experimental result, press Reed﹠amp; The Muench method calculates the 50% effective concentration (EC that compound suppresses virus
50), 50% cell growth inhibiting concentration (CC
50) and the active therapeutic index of anti-HIV-1 (Therapeutic index TI) is: TI=CC
50/ EC
50
1, cell growth survival rate (%)=experimental port OD value/control wells OD value * 100
2, the cytopathogenic inhibiting rate of HIV-1 (%)=(1-experimental port synplasm number/control wells synplasm number) * 100
3, the protection ratio of cells infected (%)=(experimental port OD value-positive control hole OD value)/(negative control hole OD value-positive control hole OD value) * 100
2. result
(1) compound is the toxic action of C8166 cell to the human T lymphocyte
Table 1 compound is to the experimental data of the toxic action of C8166 cell
(2) compound is to HIV-1
IIIBInduce the cytopathic restraining effect of C8166
Table 2. compound is to HIV-1
IIIBInduce the cytopathic restraining effect experimental data of C8166
(3) compound is to HIV-1
IIIBInfect MT
4The provide protection of cell
Table 3. compound is to experiment strain HIV-1
IIIBInfect MT
4The experimental data of cytoprotection
3. test-results gathers
Table 4: the active summary sheet as a result of compound vitro cytotoxicity and anti-HIV-1:
Compound shown in the present and HIV-1 intergrase have very high combination activity, and can effectively suppress the combination of intergrase to substrate in the substrate competition test.The present inventor also finds, the compound that embodiment 8 (IA-3) is disclosed is in external anti HIV-1 virus experiment, toxicity to the C8166 cell is less, CC50 is greater than 200 μ g/ml, the EC50 that induces the C8166 cell to form the synplasm inhibition to HIV-1 is 1.13-2.41 μ g/ml, therapeutic index TI is 177.46～73.63, has further confirmed the effect of this compounds anti HIV-1 virus.
Industrial applicibility
Of the present invention 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, advantage such as the preparation method of 3-pyrimidines has that reaction conditions gentleness, abundant raw material are easy to get, operation and aftertreatment are simple.
Of the present invention 2,4-disubstituted amido-6-replacement-[1,3,5] triazine or 1, the 3-pyrimidines the computer virtual screening and with the binding constant of HIV-1 intergrase, and in the substrate competition test, can effectively suppress the combination of intergrase to substrate.Verified the mechanism of action that anti HIV-1 virus infects.
Toxicity of compound of the present invention is very low.
Therefore, compound of the present invention can be used for preparing the medicine of treatment HIV virus infection.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101700247A CN101245051B (en) | 2005-12-22 | 2006-12-22 | 2,4-di-substituted amido-6-substituted-[1,3,5]triazine or miazines compound, preparation method, pharmaceutical combination and use of the same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510132243.1 | 2005-12-22 | ||
| CN200510132243 | 2005-12-22 | ||
| CN2006101700247A CN101245051B (en) | 2005-12-22 | 2006-12-22 | 2,4-di-substituted amido-6-substituted-[1,3,5]triazine or miazines compound, preparation method, pharmaceutical combination and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101245051A CN101245051A (en) | 2008-08-20 |
| CN101245051B true CN101245051B (en) | 2011-04-20 |
Family
ID=38188279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101700247A Expired - Fee Related CN101245051B (en) | 2005-12-22 | 2006-12-22 | 2,4-di-substituted amido-6-substituted-[1,3,5]triazine or miazines compound, preparation method, pharmaceutical combination and use of the same |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101245051B (en) |
| WO (1) | WO2007071199A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011039735A2 (en) * | 2009-10-02 | 2011-04-07 | Consiglio Nazionale Delle Ricerche | Compounds with ddx3 inhibitory activity and uses thereof |
| MX343599B (en) * | 2010-07-20 | 2016-11-11 | Vestaron Corp | Insecticidal triazines and pyrimidines. |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| CN1295566A (en) * | 1998-03-27 | 2001-05-16 | 詹森药业有限公司 | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections |
| WO2003062392A2 (en) * | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| GB2397301A (en) * | 2003-01-14 | 2004-07-21 | Novo Pharmaceuticals Ltd De | Substituted 1,3,5-triazine derivatives |
| US20040167132A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
| CN1668305A (en) * | 2002-05-13 | 2005-09-14 | 泰博特克药品有限公司 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission |
-
2006
- 2006-12-22 CN CN2006101700247A patent/CN101245051B/en not_active Expired - Fee Related
- 2006-12-22 WO PCT/CN2006/003546 patent/WO2007071199A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| CN1295566A (en) * | 1998-03-27 | 2001-05-16 | 詹森药业有限公司 | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections |
| WO2003062392A2 (en) * | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| CN1668305A (en) * | 2002-05-13 | 2005-09-14 | 泰博特克药品有限公司 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission |
| GB2397301A (en) * | 2003-01-14 | 2004-07-21 | Novo Pharmaceuticals Ltd De | Substituted 1,3,5-triazine derivatives |
| US20040167132A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101245051A (en) | 2008-08-20 |
| WO2007071199A1 (en) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101797046B1 (en) | Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same | |
| ES2293584T3 (en) | USED QUINAZOLINONE DERIVATIVES AS VANILOID ANTAGONISTS. | |
| WO2008112156A1 (en) | Chemokine receptor modulators | |
| ES2390227T3 (en) | New phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | |
| CA2874250A1 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2002509140A (en) | Triazine antiviral compounds | |
| AU2018319016A1 (en) | AHR inhibitors and uses thereof | |
| US20160024078A1 (en) | CaMKII INHIBITORS AND USES THEREOF | |
| JP2020143161A (en) | CaMKII INHIBITORS AND USES THEREOF | |
| JP2023162363A (en) | Wide-range spectrum antiviral composition and method | |
| WO2013022550A2 (en) | Small molecule inhibitors of ebola and lassa fever viruses | |
| CN106866548B (en) | 6-cyclohexylmethylpyrimidinone HIV reverse transcriptase inhibitor, its preparation method and application | |
| CN102285969A (en) | N-1-substituted piperidin-4-arylamine derivatives and preparation method and use thereof | |
| CN101245051B (en) | 2,4-di-substituted amido-6-substituted-[1,3,5]triazine or miazines compound, preparation method, pharmaceutical combination and use of the same | |
| CN118076589A (en) | An amide compound, its preparation method and pharmaceutical use | |
| ES2379242B1 (en) | CHROME DERIVATIVES | |
| CN101638391B (en) | 2-[(substituted phenylamino)carbonylmethylthio]-6-(2,6-dichlorobenzyl)-3H-pyrimidin-4-one derivatives and their preparation methods and applications | |
| CN110483487B (en) | 2-thiomethylpyrazole pyrimidone compound, preparation method thereof, pharmaceutical composition and application | |
| CN111704603B (en) | Anti-tumor compound and application thereof | |
| CN114213395A (en) | Pyrimidone acyl piperazine compound and preparation method and application thereof | |
| CN110483425A (en) | A kind of application of the acyl thiourea compound and preparation method thereof with anti-influenza A virus | |
| WO2008142623A2 (en) | Tumor necrosis factor - alpha inhibitors | |
| CN108586482A (en) | A kind of Diarylmiazines HIV-1 inhibitor of the ring containing triazole and its preparation method and application | |
| CN111285859B (en) | A class of 2,4,5-trisubstituted pyrimidine compounds targeting HIV-1 reverse transcriptase and their preparation method and application | |
| CN108218896A (en) | A kind of Thiazolopyrimidine HIV-1 reverse transcriptase inhibitor and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110420 Termination date: 20111222 |